For patients with a BRAF wild-type tumor, aspirin use after diagnosis showed a RR for overall survival of 0.74 (95% CI 0.54–1.00), and when adjusted for potential confounders this effect was more pronounced with an adjusted RR of 0.60 (95% CI 0.44–0.83, p = 0.002, Fig 3). This evidence concerns the gene BRAF and neoplasm.